


NMS-1286937

ALTERNATE NAME: 1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide
NMS1286937

CATALOG #: B2636-5 5 mg
B2636-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₄H₂₇F₃N₈O₃

MOLECULAR WEIGHT: 532.5

CAS NUMBER: 1034616-18-6

APPEARANCE: Crystalline solid

PURITY: ≥95% by HPLC

SOLUBILITY: >20 mg/ml DMSO

DESCRIPTION: NMS-1286937 a potent, small-molecule Polo-like kinase 1 (PLK1) inhibitor (IC₅₀ = 2 nM) with potential antineoplastic activity. It selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells.

STORAGE TEMPERATURE: -20°C. Protect from light

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

BI 6727 (2222)
BI-2536 (2370)
SBE13 hydrochloride (2847)
GSK461364 (2287)

DISCLAIMER: *FOR RESEARCH USE ONLY! Not to be used on humans.*